Hengeveld, P. J. http://orcid.org/0000-0002-0070-138X
Schilperoord-Vermeulen, J.
van der Klift, M. Y.
Dubois, J. M. N.
Kolijn, P. M.
Kavelaars, F. G.
Rijken, M.
Dobber, J. A.
Nasserinejad, K.
Kersting, S.
Westerweel, P. E. http://orcid.org/0000-0002-0746-7039
Kater, A. P. http://orcid.org/0000-0003-3190-1891
Langerak, A. W. http://orcid.org/0000-0002-2078-3220
Levin, M-D. http://orcid.org/0000-0003-2139-3547
Article History
Received: 2 March 2023
Revised: 30 May 2023
Accepted: 13 June 2023
First Online: 4 July 2023
Competing interests
: JMND has received research funding from Roche/Genentech. SK has received personal fees from Janssen, AbbVie, Novartis, Gilead and Celgene; and research funding from AbbVie, Janssen, AstraZeneca and Roche/Genentech. APK has received personal fees from AbbVie, LAVA, Genmab, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb; and research funding from AbbVie, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb. AWL has received research funding via an unrestricted grant from Roche-Genentech and speaker fees from Janssen. M-DL has received personal fees from AbbVie, Janssen, and Roche; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. The remaining authors declare no competing financial interests.